Uncovering repurposed medicines to fight liver fibrosis
Stanford geneticist uses Co-Scientist to help find new treatments for chronic liver disease and liver fibrosis.
More from the blog
Accelerating discovery of liver disease mechanisms
Filippo Menolascina uses Co-Scientist to identify new liver disease treatments and explain why existing drugs only help certain patients.
Related papers
Unlocking non-model organisms with CRISPR-Cas: A roadmap for sustainable biotechnology.
It is concluded that bridging the gap between foundational CRISPR research and its real-world applications is imperative and future efforts should focus on democratizing tools via open-source platforms, advancing delivery systems, and fostering sustainable innovation through synthetic biology integration to fully realize the transformative potential of genome editing in organisms beyond model organisms.
Mutation-induced phenotypic plasticity drives formation of a pro-metastatic tumour-intrinsic niche
It is argued that formation of a tumour-intrinsic niche is a prerequisite for BRAF-mutant CRC seeding to distant organs and that interference with niche formation may help avoid metastatic relapse.
Application of Human Genome Editing Technologies in the Law of Certain States
This article is devoted to the legal regulation of the use of genomic editing technology in individual states. In general, it can be stated that in most legal systems there are restrictions on genomic editing in relation to hereditary genes, however, in rare cases exceptions are allowed, which must be recognized as justified in view of the reality of threats to human life and health. Using the method of comparative legal analysis, the author identifies the most optimal experience that can be useful to the domestic system of law-making on the way to forming legislation in the field of public health protection.